Akèy › Maladi fwa steatotik › Ohio
Etid klinik pou Maladi fwa steatotik nan Ohio
15 etid pou Maladi fwa steatotik ap chèche patisipan nan sit nan Ohio.
Vil nan Ohio
Tèks ofisyèl etid la (Anglè)
A Study to Investigate Safety and Efficacy of Efimosfermin Compared With Placebo in Adult Participants With Compensated Cirrhosis Due to Metabolic Dysfunction-associated Steatohepatitis (MASH)
- GSK Investigational Site, Springboro
- GSK Investigational Site, Westlake
Ap rekriteFaz 3
Laj 18 a 75 · Tout sèks · Mizajou Sep 30, 2026 · NCT07704892Liver Cirrhosis Network Rosuvastatin Efficacy and Safety for Cirrhosis in the United States
- Cleveland Clinic, Cleveland
Ap rekriteFaz 2
Laj 18 a 75 · Tout sèks · Mizajou Sep 28, 2026 · NCT05832229A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
- Akron Gastro Research, Akron
- Dayton Gastroenterology - Beavercreek, Beavercreek
- Clinical Research Institute of Ohio - Brooklyn, Brooklyn
- ak 1 plis
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT07165028Impact of Soymilk on Liver Disease Severity of Children With Non-alcoholic Fatty Liver Disease (NAFLD)
- Cincinnati Children's Hospital Medical Center, Cincinnati
Ap rekriteFaz 2
Laj 5 a 16 · Tout sèks · Mizajou Sep 22, 2026 · NCT06133101A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
- Akero Clinical Study Site, Akron
- Akero Clinical Study Site, Springboro
- Akero Clinical Study Site, Westlake
Ap rekriteFaz 3
Laj 18 a 80 · Tout sèks · Mizajou Sep 21, 2026 · NCT06528314A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH
- GSK Investigational Site, Akron
- GSK Investigational Site, Springboro
Ap rekriteFaz 3
Laj 18 a 75 · Tout sèks · Mizajou Sep 17, 2026 · NCT07221188A Study of a Thyroid Hormone Receptor Beta Isoform (THRβ) Agonist and an Semicarbazide Sensitive Amine Oxidase (SSAO) Inhibitor, Alone and in Combination, in Adults With Presumed Metabolic Dysfunction-associated Steatohepatitis (MASH)
- Akron Gastro Research, Akron
- Digestive Specialists, Dayton
- DSI Research, Springboro
- ak 1 plis
Ap rekriteFaz 2
Laj 18 a 75 · Tout sèks · Mizajou Sep 9, 2026 · NCT07288138A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
- 89bio Clinical Study Site, Akron
- 89bio Clinical Study Site, Dayton
- 89bio Clinical Study Site, Dayton
- ak 4 plis
Ap rekriteFaz 3
Laj 18 a 80 · Tout sèks · Mizajou Sep 3, 2026 · NCT06318169A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH
- 89bio Clinical Study Site, Akron
- 89bio Clinical Study Site, Cincinnati
- 89bio Clinical Study Site, Cleveland
- ak 5 plis
Ap rekriteFaz 3
Laj 18 a 75 · Tout sèks · Mizajou Sep 3, 2026 · NCT06419374A Study to Investigate the Safety and Efficacy of GSK4532990 Compared With Placebo in Adult Participants Aged 18 to 70 Years With Alcohol-related Liver Disease
- GSK Investigational Site, Cleveland
Ap rekriteFaz 2
Laj 18 a 70 · Tout sèks · Mizajou Aug 3, 2026 · NCT06613698Fibrosis Lessens After Metabolic Surgery
- Cleveland Clinic, Cleveland
Ap rekriteFaz 4Volontè an sante akeyi
Laj 18 a 75 · Tout sèks · Mizajou Jul 31, 2026 · NCT06374875A Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASH
- GSK Investigational Site, Akron
- GSK Investigational Site, Springboro
- GSK Investigational Site, Westlake
Ap rekriteFaz 3
Laj 18 a 75 · Tout sèks · Mizajou Jul 27, 2026 · NCT07221227Milk Thistle Clinical Trial in Pediatric NAFLD
- University Hospitals Cleveland Medical Center, Cleveland
Ap rekriteFaz 2
Laj 9 a 22 · Tout sèks · Mizajou Jan 27, 2026 · NCT06477146Quantitative Ultrasound(DeepUSFF) vs MRI-PDFF for Liver Fat Assessment in MASLD
- southwoods imaging (Northeastern Ohio Radiology Research and Education Fund ), Boardman
Ap rekrite
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2025 · NCT07192159Evaluation of Non-Invasive Tests for Metabolic Liver Disease
- Ohio Clinical Trials, Columbus
Ap rekriteEtid obsèvasyon
Laj 18 a 75 · Tout sèks · Mizajou Aug 14, 2025 · NCT07122700Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.